StemCells (NASDAQ: STEM) reported Q3 EPS of ($0.14), $0.02 worse than the analyst estimate of ($0.12). Revenue for the quarter came in at $883 million versus the consensus estimate of $220 million.

For earnings history and earnings-related data on StemCells (STEM) click here.